Singapore Paincare Holdings Announces Creditors’ Voluntary Winding-Up of 51% Owned Subsidiary

Key Developments Investors Need to Know

• Voluntary Liquidation of Dermatology & Laser Specialist Clinic Pte. Ltd. (DLS):
  Singapore Paincare Holdings Limited (the “Company”) has disclosed that its 51% owned subsidiary, Dermatology & Laser Specialist Clinic Pte. Ltd. (“DLS”), will undergo a creditors’ voluntary winding-up due to its inability to continue business in view of its liabilities.
• Appointment of Provisional Liquidators:
  Tan Wei Cheong and Lim Loo Khoon of Deloitte Singapore SR&T Restructuring Services Pte Ltd have been appointed as Joint and Several Provisional Liquidators of DLS as of 2 February 2026.
• Upcoming Meetings:
  An extraordinary general meeting (EGM) of DLS’s members and a creditors’ meeting will be convened in due course. The purpose is to vote on the winding-up resolutions and to confirm the appointment of the liquidators.

Potential Impact on Shareholders & Share Price Sensitivity

• Financial Impact:
  The Company has stated that the liquidation of DLS is not expected to have any material impact on its net tangible assets or earnings per share for the current financial year. This suggests that while the winding-up is significant from an operational perspective, the financial effect on the group’s consolidated results and balance sheet is expected to be minimal.
• No Conflicts of Interest:
  The announcement confirms that, apart from their roles as directors or shareholders in the Company and/or DLS, none of the directors or controlling shareholders of Singapore Paincare Holdings has any direct or indirect interest in this winding-up process.
• Shareholder Advisory:
  Shareholders are strongly advised to exercise caution when dealing in the Company’s securities. The board recommends that shareholders refrain from taking any action in respect of their securities that could be prejudicial to their interests. Investors should await further announcements and consult professional advisors if in doubt.

Additional Details

• Regulatory Oversight:
  This announcement has been reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd., but not by the Singapore Exchange Securities Trading Limited (SGX-ST), which assumes no responsibility for the announcement’s contents.
• Continuous Updates:
  The Company has committed to updating shareholders promptly should there be any material developments regarding the winding-up of DLS.
• Contact Information:
  For further queries, shareholders may contact Mr. Pong Chen Yih, Chief Operating Officer of Novus Corporate Finance Pte. Ltd., at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

Conclusion

The winding-up of DLS, while noteworthy, is not expected to have a significant financial impact on Singapore Paincare Holdings’ consolidated results. Nevertheless, the move reflects ongoing challenges within a key subsidiary and could influence investor sentiment. Shareholders should remain vigilant and look out for further disclosures from the Company.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial advisors before making any investment decisions. The author and publisher are not liable for any losses incurred based on the information provided herein.

View Sing Paincare Historical chart here